Clinical trialNCT03521154Active, not recruitingPhase 3Interventional

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

SponsorAstraZenecaEnrollment216Non Small Cell Lung Cancer (Stage III)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Shun Lu, MD
Shanghai Chest Hospital, Shanghai, China
Principal Investigator
clinicaltrials.gov ↗
Suresh S Ramalingam, MD
Emory University School of Medicine, Atlanta, U.S.
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

118 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Research Site
Ciudad Autónoma de Bs. As., Argentina
Research Site
Ciudad Autónoma de Bs. As., Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Research Site
San Salvador de Jujuy, Argentina

Brazil

Research Site
Barretos, Brazil
Research Site
Curitiba, Brazil
Research Site
Florianópolis, Brazil
Research Site
Fortaleza, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

China

Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Jinan, China
Research Site
Linhai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Wuhan, China
Research Site
Wuhan, China
Research Site
Ürümqi, China

Hungary

Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Gyöngyös - Mátraháza, Hungary
Research Site
Pécs, Hungary

India

Research Site
Bangalore, India
Research Site
Gurgaon, India
Research Site
Hubli, India
Research Site
Karamsad, India
Research Site
Kolkata, India
Research Site
Nashik, India

78 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Osimertinib →Placebo Osimertinib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Jul 2018
Primary completion: 5 Jan 2024
Completion: 29 Oct 2027
Last update posted: 4 Aug 2026
Registered enrollment: 216
Registry id: NCT03521154

Cross-registrations

EU-CTR / CTIS (EudraCT)2018-001061-16EU-CTR / CTIS (EudraCT)2022-500860-36-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.